IDEAYA Biosciences (NASDAQ:IDYA) Issues Earnings Results, Misses Estimates By $0.14 EPS

IDEAYA Biosciences (NASDAQ:IDYA) announced its earnings results on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.14), Briefing.com reports. IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. During the same quarter last year, the company earned ($0.50) EPS.

IDEAYA Biosciences Stock Up 4.8 %

Shares of IDYA traded up $1.72 on Thursday, hitting $37.58. The company’s stock had a trading volume of 730,832 shares, compared to its average volume of 913,520. The firm’s fifty day moving average price is $38.52 and its 200-day moving average price is $41.25. IDEAYA Biosciences has a fifty-two week low of $21.76 and a fifty-two week high of $47.74. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -18.70 and a beta of 0.87.

Insiders Place Their Bets

In other news, insider Michael Anthony White sold 28,500 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total value of $1,032,840.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Yujiro S. Hata sold 56,711 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total transaction of $2,359,744.71. Following the completion of the sale, the chief executive officer now owns 677,887 shares in the company, valued at $28,206,878.07. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Michael Anthony White sold 28,500 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total value of $1,032,840.00. The disclosure for this sale can be found here. Insiders sold a total of 119,644 shares of company stock valued at $4,832,228 in the last quarter. 3.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday. The Goldman Sachs Group reduced their target price on shares of IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. Mizuho initiated coverage on shares of IDEAYA Biosciences in a research report on Monday, July 8th. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and set a $54.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IDEAYA Biosciences presently has a consensus rating of “Buy” and an average price target of $52.08.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.